Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.


CSE:PHRM - Post by User

Post by BradlTheGermanon Apr 11, 2024 2:45am
218 Views
Post# 35982685

13 trading days left !

13 trading days left !
I very much doubt that there is a leak from the FDA. Fear, doubt, nervousness, uncertainty and unprofessionalism have characterized the last 2 trading days.
 
Those who sell realize a loss - those who buy and hold have extraordinary profit prospects.

"PharmaTher's product pipeline target attractive regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway and orphan drug, fast track and breakthrough designations."
 
Fast track and breakthrough designations (!!!) from the FDA...why?
 
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

The FDA is obviously very interested in approval, especially as the study results speak for themselves.

There is a saying in Germany: "Those who shy away from risk cannot seize opportunities."

Best luck to all!
<< Previous
Bullboard Posts
Next >>